1. Systemic mycoses
- DR. ANKUR KUMAR

2. Systemic mycoses
Disease Causative agent
1. Histoplasmosis Histoplasma capsulatum
2. Blastomycosis Blastomyces dermatitidis
3. Coccidioidomycosis Cocddioides immitis
4. Paracoccidioidomycosis Paracoccidioides brasiliensis

3. HISTOPLASMOSIS
• Systemic granulomatous disease caused by a
dimorphic fungus, Histoplasma capsulatum.
• Species name is misnomer as it is not
capsulated.
• Also known as Darling's disease (because they
was first reported by Samuel Darling in1905 )

4. HISTOPLASMOSIS- Pathogenesis
• Transmitted by- inhalation of spores (i.e.
microconidia) which usually circulate in the air
after the contaminated soil is disturbed.
• Spores enter into the lungs engulfed
inside the alveolar macrophages
transform into yeast forms .
• Yeasts survive within the phagolysosome of
the macrophage by producing alkaline
substances (bicarbonate and ammonia).

5. HISTOPLASMOSIS- Clinical Manifestations
• Pulmonary hlstoplasmosis:
 Most common form.
 Acute form presents with mild flu like illness, pulmonary infiltrates
in chest X-ray with hilar or mediastinal lymphadenopadiy.
 Chronic cavitary histoplasmosis may be seen in smokers with
underlying structural lung disease.
• Mucocutaneous histoplasmosis
 Skin and oral mucosal lesions may develop secondary to
pulmonary infection.
 Oral lesions are particularly seen in Indian patients.
• Disseminated histoplasmosis:
 Develops if CMI is very low (e.g. untreated HIV infected people or
following organ transplantation).
 Common sites affected- bone marrow, spleen, liver, eyes and
adrenal glands

6. HISTOPLASMOSIS- Laboratory Diagnosis
• Specimens:
Sputum, aspirate from bone marrow & lymph
node, blood and biopsies from skin & mucosa.
• Direct microscopy:
Histopathological staining (PAS, Giemsa or GMS
stain) – Shows tiny oval yeast cells (2-4 µm size)
with narrow based budding within macrophages
with an underlying granulomatous response.

7. HISTOPLASMOSIS- Laboratory Diagnosis
• Culture:
Gold standard method of diagnosis.
Media- SDA, blood agar and BHI agar
Incubated simultaneously at 25°C and 37°C.
At 25°C:
 Mycelial phase
 Produces white to buff brown colonies, consist of 2 types of
conidia or spores:
1) Tuberculate macroconidia- typical thick walls and finger-like
projections which is a characteristic feature
2) Microconidia are smaller, thin, and smooth-walled.
At 37°C:
 Gets converted into yeast form (creamy white colonies), which is
best developed in special media like Kelley's media.

8. HISTOPLASMOSIS- Laboratory Diagnosis
• Serology:
Antibodies in serum - detected by CFT and
imununodiffusion test.
Antibodies appear after 1 month of infection; hence
are more useful in chronic stage (often negative in
early course and in disseminated stage).
 False positive result may occur due to past infection
or cross infection with blastomyces.
• Skin test:
 May be done to demonstrate delayed type hypersensitivity
response to histoplasmin antigen, which indicates prior
exposure

9. Histoplasma capsulatum (schematic diagram)
A. Yeast form;
B. Mycelial form;
C. 2-4 µm yeast cells with narrow based budding (Giemsa stain)
D. Mold form, septate thin hyphae with tuberculate macroconidia (arrows showing)

10. HISTOPLASMOSIS- TREATMENT
• Liposomal amphotericin B
 Is the antifungal agent of choice in acute pulmonary and
disseminated histoplasmosis.
• ltraconazole
Recommended for chronic cavitary pulmonary
histoplasmosis.

11. BLASTOMYCOSIS
• Also known as North American blastomycosis
or Gilchrist's disease or Chicago disease
• Is a fungal infection of humans and other
animals also- dogs and cats, caused,
Blastomyces dermatitidis.

12. BLASTOMYCOSIS- Pathogenesis
• Transmitted by
Inhalation of the conidia of B. dermatitidis.
Spores enter into the lungs, and are engulfed by
alveolar macrophages, where they get converted
into yeast phase.
This yeast expresses a 120-kDa glycoprotein called
BAD-I (B. dermatitidis adhesin-1) which is an
essential virulence factor and also a major inducer
of cellular and humoral immune responses.

13. BLASTOMYCOSIS- Clinlcal Manifestations
• Acute pulmonary blastomycosis - Most common
form.
• Extrapulmonary manifestations
Skin involvement - Most common extrapulmonary
form; characterized by either verrucous (more
common) or ulcerative type of skin lesions.
Osteomyelitis may develop along with contiguous soft
tissue abscesses and draining sinuses.
Prostate and epididymis involvement in men.
 Central nervous system (CNS) involvement has been
reported in - 40% of AIDS patients.
Brain abscess is the usual presentation, followed by
cranial or spinal epidural abscess and meningitis.

14. BLASTOMYCOSIS- Laboratory Diagnosis
• Antibody detection: lmmunodiffusion test
specific for B. dermatitidis has been developed
against yeast phase antigens such as antigen-A,
BAD- I and ASWS antigen (alkali soluble water
soluble).
• Antigen detection assay- detect Blastomyces
antigen in urine (more sensitive) and in serum is
commercially available.
• Molecular methods- DNA probe hybridization and
real time PCR

15. BLASTOMYCOSIS- Laboratory Diagnosis
• Histopathological staining of the tissue biopsy
specimens reveals thick-walled round yeast cells
of 8- 15 µm size with single broad-based budding
(figure of 8 appearance)
• Culture media - SDA, blood agar and BH I.
At 250C- Mycelia form containing hyphae with small
pear-shaped conidia are produced;
At 370C- mold to yeast conversion takes place.
• Skin test: done to demonstrate delayed type
hypersensitivity to blastomycin antigen.

16. Blastomyces
A. Schematic (Mycelial and yeast form);
B. Histopathological stain (arrow shows) broad based
budding yeast cells (figure o f 8 appearance)

17. BLASTOMYCOSIS- TREATMENT
• Liposomal amphotericin B
 is the antifungal agent of choice in most of the cases.
• ltraconazole
in immunocompetent patients with mild
pulmonary or non CNS extrapulmonary
blastomycosis

18. COCCIDIOIDOMYCOSIS
• Also called desert rheumatism or Valley fever
or California fever
• Is a systemic fungal disease caused by a
dimorphic soil dwelling fungus- Coccidioides
(C. immitis and C. posadasii).

19. COCCIDIOIDOMYCOSIS -Pathogenesis
• Transmitted by inhalation of arthroconidia.
• In lungs, they enlarge, become rounded, and
develop internal septations to form large sac like
structures of size up 10-200 µm called spherules-
encompass numerous endospores.
• Spherules may rupture and release packets of
endospores that can disseminate and develop
into new spherules.
• If spherules returned to artificial media or soil,
they revert back to the mycelial stage.

20. COCCIDIOIDOMYCOSIS - Clinlcal Manifestations
• Asymptomatic- in most of patients (60%).
• Pulmonary coccidioidomycosis - presents as
pneumonia, cavities, pleural effusion or nodule
formation.
• Skin lesions such as rashes or erythema nodosum and
arthritis with joint pain may appear secondary to
pulmonary infection particularly in women.
• Disseminated form:
Males and persons with low CMI (HIV infected patients
with CD4+ T cell count <250/ µI) are at higher risk.
Common sites for dissemination include skin, bone, joints,
soft tissues, and meninges.

21. COCCIDIOIDOMYCOSIS - Laboratory Diagnosis
• Histopathological staining
H and E stain, PAS or CMS of sputum or tissue biopsy
specimens demonstrates spherules which are large
sac like structures (20-80 µm size), have thick, double
refractile wall, and are filled with endospores
• Cultures on SDA –
 produces mycelial growth, described as fragmented hyphae
consisting of barrel-shaped arthrospores with alternate cells
distorted (empty cells)
 Coccidioides differs from other dimorphic fungi as it grows as
mold at both 25°C and 37°C in usual culture media (forms
spherules at 37°C in certain special culture media only).
 Cultures are highly infectious: lead to accidental inhalation of
spores in laboratories, require biosafety level-3 precautions.

22. COCCIDIOIDOMYCOSIS - Laboratory Diagnosis
• Serology: Antibodies are detected by
immunodiffusion test and CFT.
• Skin test: It is done by fungal extaracts
(coccidioidin or spherulin);
 produces at least a 5 mm induration within 48
hours after injection (delayed hypersensitivity
reaction) indicates past infection.

23. Cocddioides
A. Spherules (schematic);
B. Hyphae with arthroconidia (schematic);
C. Spherules (PAS staining);
D. Hyphae with arthroconidia (LPCB mount)

24. TREATMENT- Coccidioidomycosis
• Itraconazole -drug of choice
except for diffuse pneumonia with pulmonary
sequelae where amphotericin B is recommended.

25. PARACOCCIDIOIDOMYCOSIS
• Also known as South American blastomycosis,
Lutz-Splendore-de Almeida disease
• Is a systemic disease caused by the dimorphic
fungus Paracoccidioides brasiliensis.

26. Pathogenesis and clinical Manifestations
• Transmission- by inhalation of spores,
• Transform into the yeast phase in lungs.
• Occurs as two major forms.
1. Acute form (or juvenile type):
affects young adults under 30 years age.
less common variety, but more severe form, manifests as
disseminated infection involving multiple viscera and is
refractory to t/t.
2. Chronic form (or adult form):
accounts for 90% of cases
predominantly affects older men.
results from reactivation of quiescenct lung lesions.
less severe form, manifested as progressive pulmonary
disease affecting lower lobes, with fibrosis.
Skin, oral mucosal lesions and cervical lymphadenopathy

27. PARACOCCIDIOIDOMYCOSIS-Laboratory Diagnosis
• Histopathological staining - of pus, tissue biopsies or
sputum
 reveals round thick-walled yeasts, which multiple narrow-
necked buds attached circumferencially giving rise to Mickeiy
mouse or pilot wheel appearance.
• Culture on SDA
 yields mycelial form at 250C
 converts in to yeast phase at 370C when grown in BHI agar
supplemented with blood and glutamine.
• Serology:
 Antibodies are detected by immunodiffusion, and by ELISA,
using gp43 antigen of P. brasiliensis.
• Skin test:
 demonstrates delayed hypersensitivity response against
paracoccidioidin antigen.

28. Paracoccidioidomycosis
A. Schematic representation of mycelial and yeast forms;
B. Methenamine silver staining shows yeast from (pilot
wheel appearance)

29. TREATMENT- Paracoccidioidomycosis
• ltraconazole - is the treatment of choice
except for the seriously ill patients where
Amphotericin B is recommended.
Sulfonamides are effective, but the response is
slow with frequent relapses.

30. THANK
YOU